CS-121
Gene therapy / editing
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Severe Hypertriglyceridemia · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07176923 NCT07176923 · Familial Chylomicronemia Syndrome (FCS) Registry: NCT07176923 | 1 | Treatment-Emergent Adverse Events (TEAEs) (From the start of dosing through approximately 10 months of follow-up); Dose-Limiting Toxicities (DLTs) (Number and type of dose-limiting toxicities (DLTs), defined as CTCAE grade ≥3 adverse events considered possibly, probably, or definitely related to CS-121 and persisting ≥7 days, or other adverse events/laboratory abnormalities that lead to suspension o) 2026-12 | In progress: results expected 1 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other APOC3 drugs
Olezarsen, Plozasiran, HRS-7249, ION775, RBD5044 and 2 more. Compare all 8 APOC3 drugs
7 other tracked programmes target this mechanism, 6 of them ahead of this one.
This drug's own stage for Familial Chylomicronemia Syndrome: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CS-121: this drug | Phase 1 | Gene therapy / editing | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | Partial signal | NCT04568434: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. | |
| Plozasiran (Redemplo) | Approved | RNA / oligonucleotide | APOC3 | Partial signal | NCT05089084: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) | |
| Volanesorsen (Waylivra) | Phase 3 | RNA / oligonucleotide | APOC3 mRNA | Reliable signal | NCT02211209: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5) | |
| RBD5044 | Phase 2(overall) | RNA / oligonucleotide | APOC3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RN0361 | Phase 1/2(overall) | RNA / oligonucleotide | APOC3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Kylo-12 | Phase 1(overall) | RNA / oligonucleotide | APOC3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow CS-121 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.